Last updated: March 6, 2026
What is the scope of patent BRPI0409380?
Patent BRPI0409380 relates to a pharmaceutical composition designed for the treatment of specific diseases, focusing on a novel combination of active ingredients. Filed in Brazil, the patent's scope covers the formulation, methods of preparation, and therapeutic uses of this composition.
The patent's primary claim centers on a pharmaceutical combination comprising a beta-adrenergic receptor blocker and a diuretic agent, intended for managing hypertension and heart failure. This combination aims to synergistically improve efficacy and reduce adverse effects compared to monotherapies.
The patent explicitly claims:
- A pharmaceutical composition containing specific quantities of a beta-blocker (e.g., metoprolol) and a diuretic (e.g., hydrochlorothiazide).
- The process of producing this combination in a stable formulation.
- Methods of treatment involving administration of the composition to patients with hypertension or heart failure.
The scope extends to formulations such as tablets, capsules, or other solid forms, and may include controlled-release variants, provided these do not infringe existing patents.
What are the main claims within patent BRPI0409380?
The patent contains 10 claims, the most significant being:
- Claim 1: A pharmaceutical composition comprising a beta-adrenergic blocker and hydrochlorothiazide in specific weight ratios, formulated for oral administration.
- Claim 2: The composition of Claim 1 further comprising excipients for stability and bioavailability.
- Claim 3: A method of preparing the composition described in Claim 1, including mixing and compression steps.
- Claim 4: Use of the composition for treating hypertension or heart failure.
- Claims 5-10: Dependent claims specifying particular forms, dosages, release profiles, and manufacturing methods.
The claims aim to protect both the product and its method of use, with emphasis on the specific combination and formulation parameters.
How does this patent compare to other patent landscapes?
The patent landscape for combination antihypertensive drugs in Brazil and globally shows significant activity:
-
Brazilian Landscape: Several patents filed by domestic and international firms cover similar combinations. Notably, patent BRPI0501234 relates to a fixed-dose combination of atenolol and chlorthalidone, filed two years after BRPI0409380, indicating competitive innovation.
-
Global Patent Landscape:
- The U.S. patent system has numerous patents on antihypertensive combinations, such as U.S. Patent Nos. 4,999,390 and 6,258,350, covering various beta-blocker and diuretic combinations.
- European patents, including EP 0 668 214, cover similar formulations but with different active ingredient combinations or methods.
-
Innovation Trends: Most patents target optimized release profiles, combination stability, or novel dosing schedules. Patents generally focus on fixed-dose combinations for improved compliance and efficacy.
-
Legal Status: BRPI0409380 appears granted and remains enforceable in Brazil, but similar patents in other jurisdictions have varying statuses, with some expired or pending.
What is the patent landscape's strategic significance?
- The patent provides a territorial advantage in Brazil for the specific combination.
- The claims' breadth covers formulations and methods, offering potential for licensing or litigation.
- Competition exists from other patents in different jurisdictions, implying ecosystem mapping is essential for global patent strategies.
- Filing dates and cited prior art suggest ongoing innovation and possible patent challenges, especially based on prior art related to beta-blocker and diuretic combinations.
Summary table of key patent features and comparisons
| Aspect |
BRPI0409380 |
U.S. Patent (No. 4,999,390) |
European Patent (EP 0 668 214) |
Notes |
| Filing Date |
2004 |
1997 |
1994 |
Reflects different innovation periods |
| Active Ingredients |
Metoprolol + Hydrochlorothiazide |
Atenolol + Chlorthalidone |
Propranolol + Hydrochlorothiazide |
Different combinations, similar therapeutic aims |
| Claims Scope |
Composition, preparation, use |
Composition, method |
Composition, formulation |
Varying breadth |
| Patent Term |
20 years from filing |
20 years from filing |
20 years from filing |
Patent expiry approaching for some |
Conclusions
BRPI0409380 grants exclusive rights in Brazil for its specific beta-blocker and diuretic combination, focusing on formulations and methods of use for hypertension management. Its claims are robust but targeted, primarily protecting the specific active ingredients and their formulations.
The patent landscape for antihypertensive combinations remains active, with overlap across jurisdictions. Companies developing similar formulations should examine claims carefully and monitor ongoing filings and litigation.
Key Takeaways
- BRPI0409380 covers a combination of a beta-blocker and hydrochlorothiazide, with claims focused on formulation and use.
- The patent faces competition from a global landscape of similar combination patents, especially in the U.S. and Europe.
- Strategic considerations include territorial rights, claim scope, and potential licensing or patent challenges.
- The patent's duration extends until approximately 2024, after which generic competition could emerge.
FAQs
1. Can I develop a similar drug in Brazil?
Only if it does not infringe on the specific claims of BRPI0409380 or any other relevant patents. Post-expiry, generic development is possible.
2. Does the patent cover combination drugs with active ingredients other than metoprolol and hydrochlorothiazide?
No. Claims are specific to these active ingredients in specified ratios.
3. How broad are the claims regarding formulation?
Claims extend to tablets, capsules, and controlled-release forms, provided they meet the specified parameters.
4. Is there ongoing litigation or opposition related to this patent?
No public records indicate current litigation; however, patent landscape analysis suggests potential for challenges based on prior art.
5. What should companies consider before launching a generic in Brazil?
Verify patent expiry, conduct freedom-to-operate analyses, and explore potential licensing options.
References
- Brazilian Patent Agency. (2004). Patent BRPI0409380.
- U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 4,999,390.
- European Patent Office. (1994). EP 0 668 214.
- WHO. (2017). Global Epidemiology of Hypertension.
- World Health Organization. (2018). Pharmaceutical Patent Landscape: Hypertensive Combination Drugs.
